Linezolid for drug-resistant tuberculosis

Singh, Bhagteshwar; Cocker, Derek; Ryan, Hannah; Sloan, Derek J.

doi:10.1002/14651858.cd012836

Cited by 7 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 Oxazolidinones linezolid: The broad spectrum antibiotic, Linezolid is the first oxazolidinone to be approved for treating Gram-positive bacterial infections, including Mtb. 24 Linezolid's antimycobacterial properties arise from its ability to bind rRNA, prevent the formation of the translation initiation complex and eventually block bacterial protein synthesis. Associated mitochondrial toxicity in humans at current dosing levels and adverse effects complicate the long-term administration of Linezolid.…”

Section: Targeting the Dna Replication And Protein Synthesis (Transcr...mentioning

confidence: 99%

New tuberculosis drug targets, their inhibitors, and potential therapeutic impact

Shetye

Franzblau

Cho

2020

Translational Research

119

137

View full text Add to dashboard Cite

Section: Targeting the Dna Replication And Protein Synthesis (Transcr...mentioning

confidence: 99%

New tuberculosis drug targets, their inhibitors, and potential therapeutic impact

Shetye

Franzblau

Cho

2020

Translational Research

119

137

View full text Add to dashboard Cite

“…The prolonged use of linezolid carries a substantial possibility of toxicity, with the optimum dose and duration still remaining unclear. [ 60 ] At present, linezolid is the only oxazolidinone drug recommended to treat MDR and XDR‐TB. [ 61 ] According to a patient's age, body size, and renal function, the appropriate linezolid dosage should be determined.…”

Section: Advances In Preclinical Developmentmentioning

confidence: 99%

Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery

Reddy

Sinha

Kumar

et al. 2022

Archiv der Pharmazie

View full text Add to dashboard Cite

The prevalence of tuberculosis (TB) remains the leading cause of death from a single infectious agent, ranking it above all other contagious diseases. The problem to tackle this disease seems to become even worse due to the outbreak of SARS-CoV-2.Further, the complications related to drug-resistant TB, prolonged treatment regimens, and synergy between TB and HIV are significant drawbacks. There are several drugs to treat TB, but there is still no rapid and accurate treatment available.Intensive research is, therefore, necessary to discover newer molecular analogs that can probably eliminate this disease within a short span. An increase in efficacy can be achieved through re-engineering old TB-drug families and repurposing known drugs.These two approaches have led to the production of newer classes of compounds with novel mechanisms to treat multidrug-resistant strains. With respect to this context, we discuss structural aspects of developing new anti-TB drugs as well as examine advances in TB drug discovery. It was found that the fluoroquinolone, oxazolidinone, and nitroimidazole classes of compounds have greater potential to be further explored for TB drug development. Most of the TB drug candidates in the clinical phase are modified versions of these classes of compounds. Therefore, here we anticipate that modification or repurposing of these classes of compounds has a higher probability to reach the clinical phase of drug development. The information provided will pave the way for researchers to design and identify newer molecular analogs for TB drug development and also broaden the scope of exploring future-generation potent, yet safer anti-TB drugs.

show abstract

“…Following the procedure and the empiric antibiotic treatment, the patient’s condition substantially improved, and subsequent MRI of the cervical spinal cord showed regression of the radiological findings. Subsequently, linezolid and ceftazidime were discontinued, although linezolid also provided coverage for tuberculosis and brucellosis 10 11. The patient was discharged from the hospital a few days later, with antibiotic regimens covering only for tuberculosis and brucellosis, which were to be continued for 12 months and 6 weeks, respectively.…”

Section: Outcome and Follow-upmentioning

confidence: 99%

Granulomatous infective spondylitis in a patient presenting with progressive difficulty in walking: the differential between tuberculosis and brucellosis

et al. 2019

View full text Add to dashboard Cite

We report a case of infectious spondylitis in a 52-year-old woman who presented with progressive difficulty in walking. The patient had a 2-month long history of neurological symptoms, which progressed rapidly to paraplegia, following her admission. Imaging studies demonstrated the presence of vertebral lesions as well as additional tissue with inflammatory elements in the spinal canal, which caused a mass effect. In combination with the presence of increased cells and protein in the cerebrospinal fluid (CSF), the differential was steered towards causes of infectious spondylitis, primarily tuberculosis. However, brucellosis was also considered, as it is endemic in our area. Prompt surgical decompression produced biopsy samples, which confirmed the presence of granulomatous inflammation. The patient was started on an empiric regimen covering both for tuberculosis and brucellosis, and gradually regained full mobility in her lower limbs. The differential of infectious spondylitis is discussed, with an emphasis on the differentiation between tuberculosis and brucellosis.

show abstract

Linezolid for drug-resistant tuberculosis

Abstract: Linezolid for drug-resistant tuberculosis.

Cited by 7 publications

References 23 publications

New tuberculosis drug targets, their inhibitors, and potential therapeutic impact

New tuberculosis drug targets, their inhibitors, and potential therapeutic impact

Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery

Granulomatous infective spondylitis in a patient presenting with progressive difficulty in walking: the differential between tuberculosis and brucellosis

Contact Info

Product

Resources

About